Freenome, Inc.
FRNMBasis: 0 sells · 8 buys in 1M
| Date | Action | ETF | Shares | Close | Est. total |
|---|---|---|---|---|---|
| 26.08.21 | BUY | ARKG | 16,003 | $13.81 | $221.0K |
| 26.08.20 | BUY | ARKG | 46,141 | $13.51 | $623.4K |
| 26.08.19 | BUY | ARKG | 55,173 | $13.63 | $752.0K |
| 26.08.18 | BUY | ARKG | 59,279 | $13.45 | $797.3K |
| 26.08.17 | BUY | ARKG | 144,595 | $13.00 | $1.9M |
| 26.08.14 | BUY | ARKG | 45,010 | $11.56 | $520.3K |
| 26.08.13 | BUY | ARKG | 123,842 | $11.61 | $1.4M |
| 26.08.12 | BUY | ARKG | 190,403 | $11.55 | $2.2M |
Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.
Analyst Consensus
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Price Information
Trading Volume
Valuation
Financials
Profitability
Dividend
Technical
Freenome is a biotechnology company that develops blood-based tests for early cancer detection using artificial intelligence and multiomics technology. Its main offering is a colorectal cancer screening test, and it is working to expand detection to multiple cancer types through clinical studies. The company holds a strong position in the early cancer detection market by combining computational biology, machine learning, and partnerships with healthcare organizations.
AI-generated summary. Not investment advice.
Related ARK stocks
Explore companies with similar themes or neighboring ARK trading activity.